Document is current
Any future updates will be listed below
-
Authors
Mendes, Diana https://orcid.org/0000-0002-1672-4906
Averin, Ahuva https://orcid.org/0000-0002-4490-7021
Atwood, Mark
Sato, Reiko https://orcid.org/0000-0003-2785-7103
Vyse, Andrew https://orcid.org/0000-0002-0339-7491
Campling, James https://orcid.org/0000-0002-6886-8565
Hariharan, Dhwani https://orcid.org/0000-0001-7329-7376
Weycker, Derek https://orcid.org/0000-0002-5405-2215
Mugwagwa, Tendai https://orcid.org/0000-0001-7515-8548
Vietri, Jeffrey https://orcid.org/0000-0002-5610-3098
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 29 December 2025
First Online: 21 January 2026
Declarations
:
: This study was conducted using publicly available data and previously conducted studies. It does not contain any new studies with human participants or animals performed by any of the authors, and hence was not subject to institutional review.
: Not applicable.
: Selected results from this study have been presented in a poster at the 17th Vaccine Congress held in Glasgow, Scotland, from September 24–27, 2023 [ ].
: Diana Mendes, Reiko Sato, Andrew Vyse, James Campling, Tendai Mugwagwa, and Jeffrey Vietri are employees and shareholders of Pfizer. Dhwani Hariharan was employed by Avalere Health during the design and conduct of this study. Mark Atwood, Ahuva Averin, and Derek Weycker are employees of Avalere Health, which received funding from Pfizer in connection with this study and the development of this manuscript.
